CClinicalTrials.gg
CompletedNCT06082414Updated Oct 13, 2023

Systemic Management in Extremely Preterm and Extremely Low Birth Weight Infants

An observational study in Bronchopulmonary Dysplasia and Death, sponsored by Peking University. Completed at 1 site in China. Open to participants aged Up to 72 Hours, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-13.

Sponsored by Peking University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,200
Ages
Up to 72 Hours
Sex
All
01

Study summary

to estimate incidences of major complications, such as bronchopulmonary dysplasia, death, and delivery room resuscitation among extremely preterm and extremely low birth weight infants in Northern China

Read the detailed description

to estimate incidences and risk factors of bronchopulmonary dysplasia, death, and delivery room resuscitation among extremely preterm and extremely low birth weight infants in Northern China

02

Conditions studied

  • Bronchopulmonary Dysplasia
  • Death
03

In context

Bronchopulmonary Dysplasia

339 studies on the registry are indexed under Bronchopulmonary Dysplasia; 80 are open to participants now.

This study's enrollment of 1,200 is above the median of 137 across 92 observational studies indexed under Bronchopulmonary Dysplasia.

Browse Bronchopulmonary Dysplasia studies →

Lead sponsor

Peking University is the lead sponsor of 411 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 72 Hours
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

infants with a birth weight \<1000grams or a gestational age \<28 weeks;

Inclusion criteria

  1. born between January 1, 2015, and December 31, 2018;
  2. a birth weight \<1000grams or a gestational age \<28 weeks;
  3. admitted within 72 hours after birth.

Exclusion criteria

Exclusion Criteria:

No medical history in the electronic record

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,200 participants (actual)
Patient registry
No

Groups and cohorts

  • <28 weeks and <1000 grams

    By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study.

    Other: no interventions

  • <28 weeks and ≥1000 grams

    By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study.

    Other: no interventions

  • ≥28 weeks and <1000 grams

    By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study.

    Other: no interventions

Interventions

  • Otherno interventions

    no interventions because of an observational study

06

What researchers measure

Primary outcomes

  1. incidences

    to investigate incidences of bronchopulmonary dysplasia

    Time frame: at 36 weeks' corrected age (CA) or at discharge

  2. risk factors

    to investigate risk factors of bronchopulmonary dysplasia

    Time frame: at 36 weeks' corrected age (CA) or at discharge

  3. incidences of delivery room resuscitation

    to investigate incidences of delivery room resuscitation

    Time frame: on admission

  4. risk factors of delivery room resuscitation

    to investigate risk factors of delivery room resuscitation

    Time frame: on admission

07

Study locations

1 site
  • Qi Feng
    Beijing, Beijing 100034, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06082414
Lead sponsor
Peking University
Collaborators
Peking University First Hospital, Peking University People's Hospital, Peking University Third Hospital, Tianjin Central Hospital of Gynecology Obstetrics, Peking Union Medical College Hospital, Beijing Children's Hospital, Beijing Friendship Hospital, Shanxi Provincial Maternity and Children's Hospital, The Second Hospital of Hebei Medical University, Handan Central Hospital, Xingtai People's Hospital, Tianjin Medical University General Hospital, The Affiliated Hospital of Inner Mongolia Medical University, Children's Hospital of Hebei Province, Tianjin First Central Hospital, Chifeng Municipal Hospital, Tianjin Medical University Second Hospital, PLA Rocket Force Characteristic Medical Center
Responsible party
Li Shuaijun (Post doctor, Attending physician, Peking University) — Principal investigator
First posted
Oct 13, 2023
Start date
Jan 30, 2019
Primary completion
Jan 29, 2020
Completion
Jan 29, 2020
Last update
Oct 13, 2023

Study contacts

Qi Feng
study chair · Peking University First Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion